The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials

Chen, Hai-Bin; Xiu, Jiancheng; Li, Yuhui; Yu, Tian-Hao

doi:10.1016/j.thromres.2020.06.009

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, patients receiving VKAs must be closely monitored. Meta-analyses of clinical trials in patients with VTE-associated conditions other than CTEPH have shown that NOACs are as effective as VKAs in preventing VTE and cardiovascular events, with similar rates of hemorrhages [79][80][81]. Data on the efficacy and safety of VKAs and NOACs in CTEPH are, however, limited.…”

Section: Anticoagulationmentioning

confidence: 99%

Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension

Ghofrani

D’Armini

Kim

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by obstruction of the pulmonary vasculature, leading to increased pulmonary vascular resistance and ultimately right ventricular failure, the leading cause of death in non-operated patients. This article reviews the current management of CTEPH. The standard of care in CTEPH is pulmonary endarterectomy (PEA). However, up to 40% of patients with CTEPH are ineligible for PEA, and up to 51% develop persistent/recurrent PH after PEA. Riociguat is currently the only medical therapy licensed for treatment of inoperable or persistent/recurrent CTEPH after PEA based on the results of the Phase III CHEST-1 study. Studies of balloon pulmonary angioplasty (BPA) have shown benefits in patients with inoperable or persistent/recurrent CTEPH after PEA; however, data are lacking from large, prospective, controlled studies. Studies of macitentan in patients with inoperable CTEPH and treprostinil in patients with inoperable or persistent/recurrent CTEPH showed positive results. Combination therapy is under evaluation in CTEPH, and long-term data are not available. In the future, CTEPH may be managed by PEA, medical therapy or BPAalone or in combination, according to individual patient needs. Patients should be referred to experienced centers capable of assessing and delivering all options.

show abstract

Section: Anticoagulationmentioning

confidence: 99%